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Background: Minor depression is common in primary care and associated with increased health care costs. Many mildly depressed
patients are prescribed antidepressants, although there is insufficient information on the cost-effectiveness of antidepressants for
these patients. The objective of this study was to evaluate whether usual care without antidepressants is equivalent to (i.e. as
effective as and as expensive as) usual care with antidepressants in patients with minor or mild-major depression.
Methods: Severity of depression was measured using the Montgomery Asberg Depression Rating Scale (MADRS) and quality-
adjusted life-years (QALYs) using the EuroQol. Resource use was measured from a societal perspective using cost diaries.
Bootstrapping was used to analyze the cost-effectiveness data.
Results: Equivalence could not be shown for improvement in MADRS score or QALYs gained at 52 weeks. The mean (95% CI)
difference in total costs between usual care without antidepressants and usual care with antidepressants was −€751 (−3601; 1522).
Using an equivalence margin of €500 equivalence in costs could not be shown. In the cost-effectiveness analyses equivalence also
could not be shown.
Limitations: This study was underpowered for economic outcomes. Another limitation was the loss-to-follow-up.
Conclusions: Although equivalence could not be shown in the costs and cost-effectiveness analyses, 95% confidence intervals also
did not show that usual care without antidepressants was vastly superior or inferior to usual care with antidepressants. Therefore,
we recommend general practitioners to show restraint when prescribing antidepressants to mildly depressed patients.
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Mild forms of depression are common in primary care;
prevalence estimates range from 3% to 5% (Katon and
Schulberg, 1992). Minor depression is associated with
impaired functioning and well-being, a raised number of
disability days and raised health care costs (Broadhead
et al., 1990; Johnson et al., 1992; Wells et al., 1989).
Although there is insufficient evidence for the cost-
effectiveness of antidepressants in patients with non-
major depression (Ackermann and Williams, 2002; Elkin
et al., 1989), general practitioners (GPs) in The Nether-
lands regularly prescribe antidepressants to these patients
(Spies et al., 2004). Prescription of antidepressants in
patients with non-major depression is only justified if
they have additional benefits over usual care without
antidepressants. Otherwise, disadvantages like medicali-
sation, side effects and dependence on antidepressants
predominate.
Because absence of a statistically significant differ-
ence does not imply that the treatments being compared
are equivalent (Altman and Bland, 1995), we chose to
perform an equivalence trial to determine whether usual
care without antidepressants (UCnoAD) by the GP is
equivalent to (i.e. as effective as and as expensive as)
usual care with antidepressants (UCAD).
2. Methods
2.1. Setting and participants
The trial was performed in The Netherlands in 2002
and 2003. The Medical Ethical Committee of the VU
University Medical Center in Amsterdam approved the
study protocol. The methodological details of the trial
are reported in full elsewhere (Hermens et al., 2007).
Patients who were diagnosed with minor or mild-
major depression (3–6 out of 9 DSM-IV depressive
symptoms) by the GP, were eligible for the trial. Ex-
clusion criteria were: age under 18 years, currently re-
ceiving antidepressants or psychological therapy, current
psychosis, alcohol or drugs abuse, loss of a loved one or
significant other in the past 6 months, pregnant or
breastfeeding, and inability to complete questionnaires.
2.2. Design and randomisation
Economic data were collected alongside a rando-
mised controlled trial with a follow-up of 52 weeks.
Block randomisation was used to ensure equal numbers
of patients in each treatment group per GP. Allocation
schemes were generated by random number tables be-fore the start of the trial. After the baseline interview, a
member of the research team not in contact with the
patient opened the appropriate opaque sealed envelope.
2.3. Interventions
All patients were scheduled for four 10–20 min
consultations with their own GP at 2, 4, 7 and 11 weeks
after inclusion (usual care). During these consultations
patients received education, information, advice and
support based on the guidelines for the treatment of
depression of the Dutch College of General Practitioners
(van Marwijk et al., 1994).
Patients allocated to UCAD, received paroxetine at a
dose of 20 mg/day. Paroxetine was chosen because it
was the most commonly prescribed antidepressant in
The Netherlands at the time the study started (van
Marwijk et al., 2001), and no clinically meaningful
differences between antidepressants are found in pri-
mary care patients (MacGillivray et al., 2003).
During the first 3 months, GPs were asked not to
deviate from the study protocol and to refrain from
referral to mental health care providers, unless the GP
judged this to be imperative. After 3 months, treatment
could end or continue in the way the GP and patient
preferred.
2.4. Outcome assessments
The severity of depressive symptoms was assessed
using the Montgomery Asberg Depression Rating Scale
(MADRS) (Montgomery and Asberg, 1979). The
MADRS was administered at 6, 13, 26 and 52 weeks of
follow-up.
Health-related quality of life was measured with the
EQ-5D (EuroQol) at baseline and 6, 13 and 52 weeks of
follow-up (EuroQol Group, 1990). Quality Adjusted Life
Years (QALYs) were calculated by multiplying the utility
based on EQ-5D scores with the amount of time a patient
spent in this particular health state (Dolan, 1997). Tran-
sitions between health states were linearly interpolated.
2.5. Cost measurement and valuation
The economic evaluation was conducted from a so-
cietal perspective. All resource use, informal care and
absenteeism from paid and unpaid work were measured
using cost diaries over a period of 52 weeks. Medication
data were retrieved from the patient’s pharmacy. Dutch
standard costs were used to value resource use (Oosten-
brink et al., 2002). Medication was valued using prices of
the Royal Dutch Society for Pharmacy (Z-index, 2002).
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price index figures (Statistics Netherlands, 2007). Table 1
lists the cost categories and prices used in the economic
evaluation.
We calculated the costs of absenteeism from paid
work according to the friction cost approach (friction
period 123 days) using mean age- and sex-specific
incomes of the Dutch population (Koopmanschap and
Rutten, 1996; Oostenbrink et al., 2000). According to
this approach the amount of production lost due to
disease is limited to the time span needed to restore the
initial level of production. Costs of absenteeism from
unpaid work were valued at a shadow price of €9 perTable 1
Costs used in the economic evaluation
€ (2002 values) a
Direct healthcare costs
Primary care costs
General practitioner [per visit] b 18
Blood test [per sample] b 21
Urine analysis [per sample] b 14
Social worker [per visit] c 47
Psychologist [per visit] c 75
Psychotherapist [per visit] c 68
Physiotherapist
[per treatment session] b
20
Manual therapist
[per treatment session] d
31
Mensendieck therapist
[per treatment session] b
20
Dietician [per visit] c 14
Chiropractor [per treatment session] c 40
Company doctor [per visit] c 21
Secondary care costs
Psychiatrist [per visit] b 62
Psychiatric admission [per day] b 197








[per treatment session] c
43
Community care costs
Professional home care b 25
Direct non-healthcare costs
Alternative therapist c Depending on type
Informal care [per hour] b 9
Indirect costs
Absenteeism paid labour [per day] e Depending on age and sex
Absenteeism unpaid labour [per hour] b 9
a €1=.31.
b Guideline price according to Dutch guidelines.
c Price according to professional organisation or health care provider.
d Tariff of Dutch Central Organisation for Health Care Charges.
e Indirect costs for absenteeism from paid work calculated on mean
income of Dutch population according to age and sex.hour which corresponds to the hourly rate of a legally
employed cleaning lady.
2.6. Equivalence margins for costs and effects
When performing an equivalence trial a relevant dif-
ference between the treatment groups (equivalence
margin) has to be defined before the start of the study.
(Jones et al., 1996) Because we examined equivalence of
both effects and costs, we had to define a margin for both
effects and costs. A margin of 5 was chosen for the
difference in improvement in MADRS score at 52 weeks
(Malt et al., 1999) and a margin of 0.03 for the difference
in QALYs gained over 52 weeks (Lave et al., 1998). For
costs, we defined 2 visits to the GP, 1 outpatient visit and
3 days of absenteeism from paid labour as a relevant
difference (Kessler et al., 1999; Luber et al., 2000). After
valuation of this difference using Dutch guideline prices,
this resulted in an equivalence margin of €500.
2.7. Data analysis
Using the sample size calculation of Jones et al for
equivalence trials (Jones et al., 1996), it was calculated
that 84 patients per group were needed (2-sided α=0.05,
β=0.10) to detect a clinically relevant difference in
improvement on the MADRS of 5 points. Clinical
outcomes were analysed using independent t-tests. For
the treatments to be equivalent, the 95% confidence
interval (CI) around the difference in clinical outcome
between the groups, should lie between the equivalence
margins for this outcome.
CIs around the mean cost differences were estimated
using bias-corrected and accelerated bootstrapping
(2000 replications) (Efron and Tibshirani, 1993).
UCnoAD was judged equivalent to UCAD, if the 95%
CI around the difference in total costs was lying between
−€500 and €500.
Uncertainty around the incremental cost-effective-
ness ratios (ICERs) was estimated using the bias-
corrected percentile bootstrapping method (5000 repli-
cations) (Chaudhary and Stearns, 1996) and presented
on a cost-effectiveness plane (CE plane) (Black, 1990).
The equivalence margins for costs and effects were
presented on these planes. For UCnoAD to have equiv-
alent cost-effectiveness compared with UCAD, 95% of
the cost-effect pairs had to lie in the area within the
equivalence margins. The equivalence margin for total
costs may vary greatly in different settings or countries.
We addressed this uncertainty by drawing an “equiva-
lence curve”. In this curve, the probability is drawn that
UCnoAD is equivalent to UCAD (in other words, the
Table 2
Baseline characteristics of patients with complete cost data
UCnoAD (n=44) UCAD (n=45)
Age (years) [mean, SD] 48 (16) 46 (15)
Female [n, %] 32 (73%) 34 (76%)
Married [n, %] 28 (64%) 29 (64%)
Level of education [n, %]
Low 12 (27%) 16 (36%)
Medium 19 (43%) 16 (36%)
High 11 (25%) 13 (29%)
Missing 2 (5%) 0
Duration depression N3 months
[n, %]
27 (61%) 25 (56%)
PRIME-MD diagnosis a
Minor depression 8 (18%) 8 (18%)
Mild-major depression 36 (82%) 36 (80%)
Missing 0 1 (2%)
MADRS score [mean, SD] 22 (10) 22 (9)
EQ-5D utility [mean, SD] 0.64 (0.26) 0.66 (0.23)
UCnoAD = Usual Care without Antidepressant; UCAD = Usual Care
with Antidepressant; PRIME-MD = Primary Care Evaluation of
Mental Disorders; MADRS = Montgomery Asberg Depression Rating
Scale (range 0–60); EQ-5D = EuroQol.
a Minor depression=3–4 depressive symptoms and mild-major de-
pression=5–6 depressive symptoms.
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tween the equivalence margins) for various values of the
equivalence margin for costs while the equivalence
margin for effects is kept constant.
Intention-to-treat analysis usually makes the results
from two treatment groups more similar and, thus,
increases the chance of declaring equivalence. There-
fore, a per-protocol analysis (PPA), which is expected
to increase the contrast between the groups, was also
performed (Jones et al., 1996). Patients in the UCnoAD
group were included in the PPA if they received noTable 3
Mean (standard deviation) total costs (€) and differences in mean total costs
with complete cost data
UCnoAD (n=44)
Direct healthcare costs 1512 (1586)
Primary care costs 542 (492)
Secondary care costs 437 (772)
Medication costs 423 (677)
Professional home care costs 110 (393)
Direct non-healthcare costs 131 (248)
Alternative therapy costs 57 (165)
Informal care costs 75 (198)
Total direct costs 1643 (1716)
Total indirect costs 3025 (5390)
Costs absenteeism paid work 2807 (5150)
Costs absenteeism unpaid work 217 (514)
Total costs 4668 (5654)
95% confidence interval obtained by bias-corrected and accelerated bootstra
UCnoAD = usual care without antidepressants; UCAD = usual care with anantidepressant during the first 3 months of the trial, and
patients in the UCAD group if they received at least 70
defined daily doses of an antidepressant during the first
3 months of the trial.
3. Results
Of the 117 participating GPs, 59 referred 293 eligible
depressed patients, of whom 181 were included in the
study (96 UCnoAD and 85 UCAD). Complete follow-
up on all cost data was available for 89 (49%) patients.
Patients with complete follow-up were more likely to
be previously treated for depression or to have Dutch
origins and were less depressed at baseline according to
the MADRS. There were no differences in baseline
sociodemographic and clinical characteristics between
the two treatment groups for patients with complete
follow-up (Table 2).
3.1. Clinical outcomes
Full details on the clinical outcomes are presented
elsewhere (Hermens et al., 2007). In summary, equiv-
alence could not be shown for the differences in im-
provement in MADRS score (mean absolute difference
−0.81; 95% CI −5.6; 4.0) or QALYs gained (mean
difference −0.00045; 95% CI −0.093; 0.084) at
52 weeks.
3.2. Costs
Table 3 shows the mean (standard deviation) costs for
the two treatment groups. Although antidepressant costs
in the UCnoAD group were significantly lower than in(95% confidence intervals) during follow-up of 52 weeks for patients
UCAD (n=45) Difference
1331 (1197) 181 (−386; 793)
544 (557) −2 (−228; 215)
335 (856) 102 (−302; 439)
423 (389) −1 (−241; 226)
29 (145) 82 (−63; 164)
153 (316) −22 (−138; 106)
8 (41) 48 (13; 80)
145 (317) −71 (−163; 54)
1484 (1322) 159 (−498; 766)
3934 (5516) −910 (−3224; 1461)
3506 (5379) −698 (−2969; 1567)
429 (805) −212 (−457; 88)
5418 (6003) −751 (−3601; 1522)
pping.
tidepressants.
Fig. 1. a. Cost-effectiveness plane for improvement in Montgomery Asberg Depression Rating Scale (MADRS) score for usual care without
antidepressants in comparison with usual care with antidepressants. The individual points on the plane represent 5000 bootstrapped cost-effect pairs
using the bias-corrected percentile method. The central black dot indicates the point estimate of the incremental cost-effectiveness ratio. The dotted
lines indicate the equivalence margins for costs and effects. b. Equivalence curve given an equivalence margin of 5 for improvement in Montgomery
Asberg Depression Rating Scale (MADRS) score for usual care without antidepressants in comparison with usual care with antidepressants. In this
curve, the probability is drawn that UCnoAD is equivalent to UCAD (in other words, the percentage of cost-effect pairs lying in the area between the
equivalence margins) for various values of the equivalence margin for costs while the equivalence margin for effects is kept constant. The dotted line
indicates a 0.95 probability that UCnoAD is equivalent to UCAD.
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difference −104, 95%CI −158; −44), total medication
costs were not statistically significantly different be-tween the two treatment groups. Using an equivalence
margin of €500, equivalence for costs could not be
demonstrated.
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The ICER for improvement in MADRS score was
594, meaning that one point of improvement extra on the
MADRS in the UCAD group costs€594. Fig. 1a shows
the CE plane for improvement in MADRS score for
UCnoAD versus UCAD. Equivalence of UCnoAD in
comparison with UCAD treatment could not be shown.
Fig. 1b shows the equivalence curve for improvement in
MADRS score at 52weeks. It can be seen from this curve
that UCnoAD is equivalent to UCAD for an equivalence
margin of €3520. Equivalence of UCnoAD in compar-
ison with UCAD for QALYs gained could also not be
shown.
3.4. Per-protocol analysis
Thirty-two patients in the UCnoAD group and 34
patients in the UCAD group were included in the per-
protocol analysis. Equivalence could not be shown for
improvement in MADRS score or QALYs gained.
4. Discussion
It could not be demonstrated that UCnoAD was
equivalent to UCAD in primary care patients with minor
or mild-major depression. However, the difference in
total costs was small in relation to the mean total costs.
Presentation of 95% CIs allowed us to test for statistical
superiority of UCnoAD versus UCAD. Although the
95% confidence limits included large cost differences in
either direction, UCnoAD was not vastly superior or
inferior to UCAD. Based on this and the disadvantages
of antidepressant use, we recommend GPs to show
restraint when prescribing antidepressants to patients
with minor or mild-major depression.
As stated before, the equivalence margin for total costs
may vary greatly in different settings or countries. Pre-
sentation of the CI around the cost differences allows
readers to draw conclusions for margins that reflect their
specific circumstances. Presentation of an equivalence
curve makes it possible for readers to estimate the prob-
ability that UCnoAD is as effective as and as expensive as
UCAD for an equivalencemargin for total costs that better
reflects their circumstances.
An important limitation is that our study was under-
powered for economic outcomes which is reflected in
the wide CIs. This is a common problem in economic
evaluations. Because the distribution of cost data typi-
cally is heavily skewed, large numbers of patients are
needed (Briggs, 2000). In equivalence trials even larger
sample sizes are needed (Jones et al., 1996). However, itmay be considered unethical to continue a trial beyond
the point at which clinical superiority has been demon-
strated (Briggs, 2000).
Another possible source of bias was the high loss-to-
follow-up. However, similar results of an imputed
analyses using the Expectation Maximization algorithm
incorporated in SPSS 10.1 (SPSS Inc., 2000) suggest
that the effect of this bias was limited.
5. Conclusion
Although equivalence could not be shown in the costs
and cost-effectiveness analyses, 95% CIs also did not
show that UCnoAd was vastly superior or inferior to
UCAD. Considering the disadvantages of antidepressant
use, we recommend GPs to show restraint when pre-
scribing antidepressants to this group of patients. Future
research should investigate the benefits of antidepressants
for primary care patients with minor and mild-major de-
pression further.Role of funding source
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